Circio enters fully funded feasibility study with major global pharmaceutical corporation

18 Nov 2025 07:00 CET

Oslo, Norway, 18 November 2025 -- Circio Holding ASA (OSE: CRNA), a
biotechnology company developing novel circular RNA expression technology for
gene and cell therapy, today announces that it has entered an agreement with
one of the major global pharmaceutical corporations to conduct a feasibility
study of circVec-enhanced gene therapy.

The feasibility study involves testing of Circio's circVec circular RNA
expression technology for delivery with AAV vectors in a specific therapeutic
area. The project will be performed by Circio and is fully funded by the
pharmaceutical company. The agreement does not include any downstream rights
or obligations on either party.

"Following the presentation of pre-clinical data showing up to 40-fold
advantage for circVec vs. conventional AAVs at major scientific conferences in
2025, Circio has attracted growing interest from a range of prospective gene
therapy collaboration partners," said Dr. Erik Digman Wiklund, CEO of Circio.
"Today, Circio has entered its first feasibility study with a major
pharmaceutical company. This feasibility study will allow us to broaden the
scope of our AAV gene therapy evaluation and serves as an important
endorsement of the potential of the circVec platform. We are in parallel
exploring opportunities to further expand our gene therapy activities through
additional partnerships in other therapeutic areas where circVec has shown
promise in pre-clinical studies."

About Circio
Building circular RNA expression systems for enhanced gene and cell therapies

Circio Holding ASA is a biotechnology company developing novel circular RNA
expression technology for gene and cell therapy.

Circio has established a unique circular RNA (circRNA) vector expression
technology for next generation RNA, DNA and viral therapeutics. The
proprietary circVec platform is based on a modular genetic construct designed
for efficient biogenesis of multifunctional circRNA inside target cells. The
circVec platform has applications in multiple therapeutic settings, including
genetic medicine, cell therapy and chronic disease. It has demonstrated
75-fold increased RNA half-life and up to 40-fold enhanced protein expression
vs. conventional mRNA-based viral and non-viral vector systems, with the
potential to become a new gold-standard gene expression technology. The
circVec R&D activities are being conducted by the wholly owned subsidiary
Circio AB in Stockholm, Sweden.

In parallel, Circio is continuing to develop its legacy immuno-oncology
program, TG01, through cost-efficient external academic and industry
collaborations. TG01 targets RAS-mutated cancers and is being tested in two
clinical trials in Norway and the USA. TG01 is a therapeutic peptide vaccine
adjuvanted by STIMULON QS-21 licensed from Agenus Inc.

This information is considered to be inside information pursuant to the EU
Market Abuse Regulation (MAR) and is subject to the disclosure requirements
pursuant to MAR article 17 and section 5-12 of the Norwegian Securities
Trading Act. The information was submitted for publication at 2025-11-18 07:00
CET.

This stock exchange announcement was published by Mats Hermansen, VP Finance,
on behalf of the Company, at the time and date stated above in this
announcement.

More information:
Access the news on Oslo Bors NewsWeb site